852146-04-4

Basic information

• Product Name: 5-(2-phenoxyphenyl)furan-2-carboxylic acid methyl ester
• Synonyms: 5-(2-phenoxyphenyl)furan-2-carboxylic acid methyl ester
• CAS NO: 852146-04-4
• Molecular Weight: 294.307
• Mol File: 852146-04-4.mol

Chemical Properties

• CAS DataBase Reference: 5-(2-phenoxyphenyl)furan-2-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(2-phenoxyphenyl)furan-2-carboxylic acid methyl ester(852146-04-4)
• EPA Substance Registry System: 5-(2-phenoxyphenyl)furan-2-carboxylic acid methyl ester(852146-04-4)

Safety Data

• Hazardous Substances Data: 852146-04-4(Hazardous Substances Data)

Upstream product

• 2527-99-3 methyl 5-bromo-2-furoate 
• 108238-09-1 2-phenoxyphenylboronic acid 

Relevant articles and documents

(5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1

A series of (5-arylfuran-2-ylcarbonyl)guanidines was synthesized and evaluated for the NHE-1 inhibitory activity and cardiprotective efficacy against ischemia-reperfusion injury. Starting with (5-phenylfuran-2-ylcarbonyl) guanidine 47 with a moderate inhibitory effect on NHE-1, the compounds with various substituents at the phenyl ring were investigated with the aim to optimize the potency. In this study, the 2,5-disubstituted compounds appeared to have better activities than the other analogues, and the 2-methoxy-5- chlorophenyl compound 85 was found as a potent inhibitor of NHE-1 (IC 50 = 0.081 μM). Furthermore, 85 showed a marked reduction of infarct size in the rat myocardial infarction model in vivo and significant improvement of cardiac contractile function in the isolated rat heart ischemia model in vitro.

FURANCARBONYLGUANIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The present invention relates to furancarbonylguanidine derivatives, a preparation method thereof and a pharmaceutical composition comprising the same. Furancarbonylguanidine derivatives of the present invention inhibit NHE-1 (sodium-hydrogen exchanger isoform 1), which helps recovery of heart function damaged from ischemia/ reperfusion and decreases myocardial infarction rate, indicating that they have protective effect on myocardial cells. Thus, furancarbonylguanidine derivatives of the present invention can be ef-fectively used for the prevention and the treatment of ischemic heart diseases such as myocardial infarction, arrhythmia, angina pectoris, etc, and also a promising candidate for a heart protecting agent applied to reperfusion therapy including thrombolytics or cardiac surgery including coronary artery bypass graft, percutaneous transluminal coronary angioplasty, etc.